 BriaCell Therapeutics Corp NASDAQ: BCTX has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation immuno-oncology imaging agents and radiopharmaceutical therapies. Under the agreement terms, ImaginAb will supply clinical doses of its CD8 ImmunoPET technology 89Zr-Df-Crefmirlimab to BriaCell for use in BriaCells ongoing Phase 12a study with Incyte Corporation NASDAQ: INCY in metastatic or locally recurrent breast cancer patients. 